Status:
RECRUITING
The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density
Lead Sponsor:
Herlev Hospital
Conditions:
Chronic Kidney Disease Mineral and Bone Disorder
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The prevalence of chronic kidney disease (CKD) in the adult population is estimated to 10%. CKD increases risk of bone fractures, cardiovascular disease and death. The main role of parathyroid hormone...
Detailed Description
The prevalence of chronic kidney disease (CKD) is estimated to afflict 10 % of the adult population, and it is increasing world-wide. CKD is a devastating disease due to the risk of kidney failure and...
Eligibility Criteria
Inclusion
- ≥50 years of age at screening
- CKD G4-5nonD (eGFR \< 30 mL/min/1.73m2) based on local laboratory assessment of serum creatinine and eGFR estimated by the CKD-EPI formula)
- Plasma PTH \> upper normal limit of local laboratory reference range (\> 8,5µmol/L) and/or treated with active vitamin D (Alphacalcidol) or calcimetics (Cinacalcet) initially
- Written informed consent
Exclusion
- Patients who have received a kidney transplant
- Patients receiving treatment with specific anti-osteoporosis medication (denosumab/bisphosphonates) (because of the profound effect on calcium/phosphate fluxes and BMD)
Key Trial Info
Start Date :
November 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT07171216
Start Date
November 20 2025
End Date
September 1 2027
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, outpatient clinic, Herlev Hospital
Herlev, Capital Region, Denmark, 2730